BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30256029)

  • 1. Undetectable Serum Levels of Anti-Müllerian Hormone in Women with Ovarian Hyperstimulation Syndrome During In Vitro Fertilization and Successful Pregnancy Outcome: Case Report.
    Grbavac I; Zec I; Ljiljak D; Rakoš Justament R; Bukovec Megla Ž; Kuna K
    Acta Clin Croat; 2018 Mar; 57(1):177-180. PubMed ID: 30256029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of anti-Müllerian hormone in predicting pregnant outcomes of polycystic ovary syndrome patients undergone assisted reproductive technology].
    Li Y; Tan JQ; Mai ZY; Yang DZ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jan; 53(1):23-30. PubMed ID: 29374882
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta-analysis.
    Bhide P; Pundir J; Gudi A; Shah A; Homburg R; Acharya G
    Acta Obstet Gynecol Scand; 2019 Oct; 98(10):1235-1244. PubMed ID: 30993683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated with Ovarian Hyperstimulation Syndrome (OHSS) Severity in Women With Polycystic Ovary Syndrome Undergoing IVF/ICSI.
    Sun B; Ma Y; Li L; Hu L; Wang F; Zhang Y; Dai S; Sun Y
    Front Endocrinol (Lausanne); 2020; 11():615957. PubMed ID: 33542709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Müllerian hormone dynamics during GNRH-antagonist short protocol for IVF/ICSI in women with varying ovarian reserve levels.
    Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
    Minerva Ginecol; 2017 Apr; 69(2):128-134. PubMed ID: 27310675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dynamics of serum anti-Mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders.
    Weintraub A; Margalioth EJ; Chetrit AB; Gal M; Goldberg D; Alerhand S; Eldar-Geva T
    Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():163-7. PubMed ID: 24630573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan.
    Tremellen K; Zander-Fox D
    Aust N Z J Obstet Gynaecol; 2015 Aug; 55(4):384-9. PubMed ID: 26230428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negligible serum anti-müllerian hormone: pregnancy and birth after a 1-month course of an oral contraceptive, ovarian hyperstimulation, and intracytoplasmic sperm injection.
    Tocci A; Ferrero S; Iacobelli M; Greco E
    Fertil Steril; 2009 Jul; 92(1):395.e9-395.e12. PubMed ID: 19410249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive value of anti-Mullerian hormone levels in serum and follicle fluid for IVF-ET outcomes in patients with polycystic ovarian syndrome].
    Chen X; Yin M; Ye D; He Y; Chen S
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Apr; 33(4):546-9. PubMed ID: 23644117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between serum AMH levels and IVF/ICSI outcomes in patients with polycystic ovary syndrome: a systematic review and meta-analysis.
    Yuwen T; Yang Z; Cai G; Feng G; Liu Q; Fu H
    Reprod Biol Endocrinol; 2023 Oct; 21(1):95. PubMed ID: 37872575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An AMH-based FSH dosing algorithm for OHSS risk reduction in first cycle antagonist protocol for IVF/ICSI.
    Sopa N; Larsen EC; Westring Hvidman H; Andersen AN
    Eur J Obstet Gynecol Reprod Biol; 2019 Jun; 237():42-47. PubMed ID: 31009858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome.
    Das M; Son WY; Buckett W; Tulandi T; Holzer H
    Reprod Biomed Online; 2014 Nov; 29(5):545-51. PubMed ID: 25262236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follicular aspiration during the selection phase prevents severe ovarian hyperstimulation in patients with polycystic ovary syndrome who are undergoing in vitro fertilization.
    Zhu WJ; Li XM; Chen XM; Zhang L
    Eur J Obstet Gynecol Reprod Biol; 2005 Sep; 122(1):79-84. PubMed ID: 16154042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the outcome of different protocols of in vitro fertilization with anti-Muüllerian hormone levels in patients with polycystic ovary syndrome.
    Chen Y; Ye B; Yang X; Zheng J; Lin J; Zhao J
    J Int Med Res; 2017 Jun; 45(3):1138-1147. PubMed ID: 28449632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on clinical effect on infertility women with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer].
    Yu R; Lin J; Zhao JZ; Wang PY; Xiao SQ; Zhang W
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):250-4. PubMed ID: 22781109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Müllerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation.
    Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
    Minerva Ginecol; 2017 Jun; 69(3):225-232. PubMed ID: 27352270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of dyslipidemia on IVF/ICSI pregnancy outcome in patients with polycystic ovary syndrome].
    Li X; Ding W; Liu JY; Mao YD; Huang J; Wang W; Ma X
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):402-408. PubMed ID: 29961283
    [No Abstract]   [Full Text] [Related]  

  • 19. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
    Zhu YM; Gao HJ; He RH; Huang HF
    Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.